Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017 (2017), Article ID 7365937, 8 pages
https://doi.org/10.1155/2017/7365937
Research Article

Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

1Department of Medicine, University of Toronto, Toronto, ON, Canada
2Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
3Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
4Mount Sinai Hospital Centre for Inflammatory Bowel Disease, University of Toronto, Toronto, ON, Canada
5Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, ON, Canada

Correspondence should be addressed to Geoffrey C. Nguyen; ac.otnorotu@neyugn.ffoeg

Received 21 September 2016; Accepted 13 December 2016; Published 23 January 2017

Academic Editor: Mark Borgaonkar

Copyright © 2017 Amir Rumman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [1 citation]

The following is the list of published articles that have cited the current article.

  • Holly Mathias, Sander Veldhuyzen van Zanten, Olga Kits, Courtney Heisler, and Jennifer Jones, “Patient-ly Waiting: A Review of Patient-Centered Access to Inflammatory Bowel Disease Care in Canada,” Journal of the Canadian Association of Gastroenterology, 2018. View at Publisher · View at Google Scholar